MORGANTOWN, W.Va., Jan. 25, 2012 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. ("Protea"), a leader in the field of bioanalytics, announced today the use of its proprietary LAESI® (Laser Ablation Electrospray Ionization) technology to identify novel biomarkers of virally-infected cells.
